Skip to Content
Merck
All Photos(1)

Key Documents

QBD10867

Sigma-Aldrich

SPDP-dPEG®36-NHS ester

>95% (HPLC)

Synonym(s):

OPSS-PEG1500-NHS ester, OPSS-PEG36-NHS ester, SPDP-PEG-NHS ester, SPDP-PEG36-NHS ester

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C87H161N3O41S2
Molecular Weight:
1969.33
MDL number:
UNSPSC Code:
12352108
NACRES:
NA.22

Assay

>95% (HPLC)

form

solid or viscous liquid

reaction suitability

reaction type: Pegylations

polymer architecture

shape: linear
functionality: heterobifunctional

shipped in

ambient

storage temp.

−20°C

Features and Benefits

SPDP-dPEG36-NHS ester is an amphiphilic, water-soluble PEGylation reagent that is designed to crosslink amines and free thiols. SPDP (also referred to as orthopyridyl disulfide, or OPSS) reacts with sulfhydryl groups to form disulfide bonds. The N-hydroxysuccinimidyl (NHS) ester reacts with free amines to form amide bonds. The single molecular weight, discrete chain length polyethylene glycol (dPEG) chain is 115 atoms (137.8 Å) long. SPDP-dPEG36-NHS ester is used like SPDP and its related hydrophobic products. However, the water-soluble dPEG product prevents hydrophobicity-triggered precipitation of compounds to which it is conjugated. SPDP-dPEG36-NHS ester is a monodisperse equivalent of the polymeric PEG1500.

Legal Information

Products Protected under U.S. Patent #s 7,888,536 & 8,637,711 and European Patent #s 1,594,440 & 2,750,681
dPEG is a registered trademark of Quanta BioDesign

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Mao Ouyang et al.
PloS one, 11(2), e0148139-e0148139 (2016-02-02)
Even when treated with aggressive current therapies, most patients with glioblastoma survive less than two years. Rapid tumor growth, an invasive nature, and the blood-brain barrier, which limits the penetration of large molecules into the brain, all contribute to the

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service